Zogenix Announces Agreement of Sale of Zohydro(R) ER

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Zogenix Announces Agreement of Sale of Zohydro(R) ER Business to Pernix for $100 Million at Closing Plus Potential Milestones of $283.5 Million

Enables planned implementation of new strategic focus to developing a late-stage, high-value CNS pipeline

Conference Call and Webcast on Tuesday, March 10, at 4:30 p.m. ET

Agreement Terms:

  • $100 million in upfront consideration comprised of $30 million in cash, $20 million in Pernix common stock and a $50 million short term promissory note
  • $12.5 million milestone payment for approval of ZX007 abuse-deterrent extended-release hydrocodone tablet (the Altus formulation)
  • Up to $271 million in potential sales milestones with first being $7.5 million upon aggregate net sales reaching $75 million in a single calendar year

SAN DIEGO, March 10, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that it has entered into a definitive agreement to sell its Zohydro ® ER (hydrocodone bitartrate) business to Pernix Therapeutics (Nasdaq: PTX ) for $100 million plus regulatory and sales milestones up to $283.5 million. Both companies plan to transition the Zogenix sales team and other select employees to Pernix.

This transaction enables Zogenix to strategically shift focus to its late-stage CNS clinical pipeline highlighted by two promising product candidates:

  • ZX008, which has orphan drug designation in the US and EU for the treatment of Dravet syndrome and is expected to enter Phase 3 development this year, and;
  • Relday, a unique long-acting injectable formulation of risperidone for the maintenance treatment of schizophrenia that is expected to be ready for Phase 3 studies in the first half of 2016.

The sale of Zohydro ER to Pernix significantly reduces operating expenses, eliminates all R&D expenses related to ongoing abuse-deterrent formulations, and further enhances the Company's financial strength with non-dilutive capital.

Roger Hawley, chief executive officer of Zogenix said, "The submission and recent approval of the supplemental New Drug Application (sNDA) for Zohydro ® ER with BeadTek™ was an important catalyst for increasing strategic interest in the brand. We are very pleased to have selected Pernix for this transaction as we believe they are well positioned to continue raising awareness of the important clinical benefits of Zohydro ER for patients suffering with severe chronic pain who are in need of around-the-clock opioid therapy. As a further benefit to those  involved with Zohydro ER, upon closing both companies plan to transition the Zogenix sales team and other select commercial and medical affairs employees to Pernix. This will help ensure uninterrupted customer support, a smooth transition and continued growth of the product. We thank our entire commercial and medical organizations for their achievements during the product's first year on the market and look forward to continued efforts in the coming months by our sales team in driving adoption of Zohydro ER in the pain community."

Terms of the agreement

Under terms of the agreement, at closing, Pernix will pay Zogenix $30 million in cash, $20 million in common stock and provide a $50 million short-term promissory note. Ten percent of the cash consideration will be deposited into escrow to fund potential indemnification claims for a period of 12 months, plus up to an additional $7 million to be deposited into escrow upon repayment of the promissory note. The Company is also eligible to receive $12.5 million upon approval of ZX007, a tablet formulation of extended-release hydrocodone with abuse-deterrent properties which is currently in development in collaboration with Altus Formulation. In addition, Zogenix is eligible to receive cash payments of up to $271 million based on the achievement of pre-determined annual product sales milestones for Zohydro ER and ZX007. Pernix will also purchase a pre-defined amount of Zohydro ER product inventory.

The Zohydro ER NDA and related investigational new drug applications will be transferred to Pernix immediately upon closing and Pernix will assume responsibility for Zogenix's royalty and manufacturing obligations to Daravita Limited, an indirect wholly-owned subsidiary of Alkermes plc. Upon closing, Pernix will also assume regulatory and financial responsibility for the ongoing efforts related to amending the Zohydro ER label to include abuse-deterrent claims and for the development of ZX007, with Zogenix providing assistance in the development of both programs under a Transitional Services Agreement for up to 18 months following closing. The transaction is expected to close in April 2015, subject to customary closing conditions. 

Leerink Partners LLC acted as financial advisor and Latham & Watkins LLP acted as legal advisor to Zogenix on the transaction.

Conference Call

Further comments regarding this transaction will be discussed during a conference call and webcast today, March 10, 2015, at 4:30 pm ET.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (877) 417-5253 (U.S.) or (315) 625-3082 (International); participant passcode: 85134635.

About Zogenix

Zogenix, Inc. (Nasdaq: ZGNX ) is a pharmaceutical company committed to developing and commercializing therapies that address specific clinical needs for people living with pain-related conditions and CNS disorders who need innovative treatment alternatives to help them return to normal daily functioning.

Forward-Looking Statements

Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding: the timing and likelihood of closing the Zohydro ER transaction; the potential to receive future milestone payments from the Zohydro ER transaction and the potential effect on operating expenses of Zogenix following the closing; Zogenix's strategy on advancing Zogenix's novel pipeline in CNS disorders; and the timing of the commencement of clinical trials for ZX008 and Relday. Actual results may differ from those set forth in this press release due to the risk and uncertainties inherent in Zogenix's business, including, without limitation: the uncertainty of approval under the Hart Scott Rodino Antitrust Improvements Act for the proposed sale of Zohydro ER; the parties' ability to satisfy the conditions to closing for the proposed transaction on the anticipated timeline or at all; difficulties or delays relating to the development, testing and manufacturing of and obtaining regulatory approval for ZX008 or Relday; Zogenix's dependence on third parties to develop ZX008 and Relday; Zogenix may require additional capital and may not be able raise sufficient capital when needed, on acceptable terms or at all; Pernix Therapeutic's ability to repay the promissory note when expected; the value of the stock consideration is subject to changes based on fluctuations in the value of Pernix Therapeutic's common stock; and other risks detailed in Zogenix's prior press releases as well as in public periodic filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Zohydro ® ER is a registered trademark of Zogenix, Inc.

BeadTek™ is a trademark used under license by Zogenix

Investors Zack Kubow |The Ruth Group 646.536.7020 | Media David Polk | Chandler Chicco Companies 310.309.1029 |

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NextPatient’s KLAS Marks Signal Specialty Workflow Fit

Updated Category News Views 22

A 93.3 score in healthcare software deserves a second look. Not a victory lap, not a drumroll—just a serious look at whether the product is solving an annoying, expensive operational problem for specialty practices. NextPatient’s recognition in the 2026 KLAS Emerging Solutions Top 20 Report lands in that category. The company placed in the top five for improving...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 157

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups

Updated Category News Views 127

Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 64

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 130

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 24

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 194

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 0

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
Utility Global’s India Steel Move Needs Hard Numbers

Updated Category News Views 104

Steel decarbonization announcements can sound enormous before a single bolt gets tightened. Utility Global says it plans to deploy its first industrial H2Gen project in India with Tata Steel, and that is plainly worth watching. Tata Steel is a serious industrial name, India is a consequential steel market, and any technology that can credibly lower emissions from heavy...

Continue Reading
Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 78

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading

Top 5 Most Recently Viewed Articles

Future Prospects of the Aluminum Die Casting Machine Market

Updated Category News Views 293

Growing Demand for Aluminum Die Casting Machines The Aluminum Die Casting Machine market is set to experience notable growth, with expectations to reach a significant market value of around $4.2 billion soon. Projections indicate that this sector could expand at a compound annual growth rate (CAGR) of 6.5% over the upcoming years, potentially hitting approximately $7.3...

Continue Reading
Upcoming Class Action Against Match Group, Inc. (MTCH)

Updated Category News Views 160

Upcoming Class Action Against Match Group, Inc. (MTCH) The Gross Law Firm recently announced a class action notice aimed at shareholders of Match Group, Inc. (NASDAQ: MTCH). This notice serves as an important call to action for shareholders who purchased shares during a specified class period. The firm encourages these individuals to reach out regarding their potential...

Continue Reading
Unveiling Hidden Treasures of Giza at Cosmic Summit 2025

Updated Category News Views 589

Unveiling Hidden Treasures of Giza at Cosmic Summit 2025 Get ready for an exciting event that promises to shed light on groundbreaking findings beneath the iconic Pyramids of Giza! The Cosmic Summit 2025 presents an exclusive opportunity for journalists to engage with distinguished researchers from the Khafre Research Project. Their innovative use of acoustic and radar...

Continue Reading
Impacts of Recent Class Action on WPP plc Investors' Rights

Updated Category News Views 251

Understanding the Class Action Against WPP plc Recently, a significant class action lawsuit has been initiated against WPP plc (NYSE: WPP), raising important issues for its shareholders. The accusations suggest that the company's leadership misrepresented the reliability of its revenue forecasts and growth potential, all while downplaying risks associated with...

Continue Reading
Texaf Secures EUR 5.39 Million for Sustainable Development

Updated Category News Views 47

Texaf's Strategic Development in Urban Infrastructure Texaf is taking significant strides in urban development with its recent project, the Petit-Pont building. The company is set to benefit from a substantial investment of EUR 5.39 million coming from the SFA Congo and African Rivers Fund IV LP. This initiative not only reflects Texaf's commitment to enhancing...

Continue Reading